Kiniksa Pharmaceuticals International, plc
KNSAKiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing differentiated therapies for patients with debilitating cardiovascular and autoimmune diseases.
Earnings
Next report
Oct 27, 2026 (in 3 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing differentiated therapies for patients with debilitating cardiovascular and autoimmune diseases. The company leverages a data-centric approach to identify and advance biologic assets that address significant unmet medical needs. Its primary value proposition is centered on its commercial-stage interleukin-1 inhibitor and a pipeline of monoclonal antibodies targeting inflammatory pathways.
Kiniksa is a commercial-stage leader in the recurrent pericarditis market with a specialized focus on IL-1 and CD40-CD154 pathway inhibition.
FAQ
- What is Kiniksa Pharmaceuticals International, plc's market cap?
- Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of $5.7B and trades on NASDAQ.
- What is Kiniksa Pharmaceuticals International, plc's revenue and profitability?
- Kiniksa Pharmaceuticals International, plc generated $840.8M in trailing twelve-month revenue with net income of $80.7M, representing a net margin of 9.6%. Gross margin stands at 89.8%, with free cash flow of $182.8M. These figures are based on the Q2 2026 filing.
- Who are Kiniksa Pharmaceuticals International, plc's competitors?
- Kiniksa Pharmaceuticals International, plc's key competitors include Aurinia Pharmaceuticals Inc, Scienture Holdings, Inc. Common Stock, Cumberland Pharmaceuticals Inc, and others. These companies compete in similar markets and product categories.
- Who does Kiniksa Pharmaceuticals International, plc partner with?
- Kiniksa Pharmaceuticals International, plc's notable partners include Regeneron Pharmaceuticals, Inc., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Samsung Biologics, and others.
- Where is Kiniksa Pharmaceuticals International, plc headquartered?
- Kiniksa Pharmaceuticals International, plc is headquartered in Bermuda and employs approximately 297 people. It has been publicly traded since 2018.
